Investors wants to see IDTs marketing partner Mayne Pharma launching Temozolomide and the cash starting to flow. If the half yearly can report income growth of significant proportions the share price will reflect a P/E ratio that shows investors believe in the future growth potential. The cash from the Cmax sale will slowly disappear over the next 12 months if there are further delays.
I'rom Group to buy CMAX Pty Ltd from IDT Australia, page-11
Add IDT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $45.13M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 10.5¢ | $2.751K | 25.49K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 72418 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 19572 | 1 |
View Market Depth
| Last trade - 15.42pm 15/11/2024 (20 minute delay) ? |
| IDT (ASX) Chart |